We performed a postmarketing surveillance study to determine the efficacy and safety of the oral quinolone antibacterial agent, garenoxacin (Geninax ® Tablets 200 mg), against bacterial pneumonia.
Text (1) Introduction
Garenoxacin (GRNX) is an oral quinolone antibiotic manufactured by Toyama Chemical Co., Ltd. (Tokyo, Japan); the company obtained the approval for manufacturing and marketing this medication in July 2007 under the product name Geninax ® Tablets 200 mg. GRNX has a novel and unique chemical structure with lack of fluorine atom at the 6-position of the quinolone skeleton, which is normally considered essential to the antibacterial activity of conventional fluoroquinolones. GRNX shows excellent antibacterial activity against major bacterial pathogens in respiratory and otorhinolaryngological infections by inhibiting type II topoisomerases (DNA gyrase and topoisomerase IV), which are involved in bacterial DNA replication. In addition, GRNX shows strong antibacterial activity against penicillin-resistant Streptococcus pneumoniae, the increasing prevalence of which in the recent years has become a cause of concern [1, 2]. Further, because this drug shows a large AUC [3] and good tissue penetration [4, 5] after administration of a single dose of 400 mg/day, plasma concentrations in excess of the mutant prevention concentration for S. pneumoniae and Staphylococcus aureus were obtained for more than 24 h. Thus, GRNX is expected to prevent the emergence of drug-resistant strains [6] .
In the clinical development study of GRNX, however, evaluable patients were limited to those who met strict inclusion and exclusion criteria to accurately assess the efficacy and safety of GRNX. Such development study might not necessarily reflect the actual patient population. Thus, we conducted a study in patients treated with GRNX in daily clinical practice basis.
In this study, we performed a specified postmarketing surveillance study to confirm the efficacy and safety of GRNX against bacterial pneumonia (including community-acquired pneumonia and nursing and healthcare-associated pneumonia [NHCAP] , not including hospital-associated pneumonia) in daily clinical practice. We collected data regarding efficacy, safety, and causative bacterial pathogens in patients with bacterial pneumonia with various backgrounds.
(2) Patients and methods
(2)-1 Target patients
The study was conducted in patients who were treated at 174 medical institutions 3 across Japan between October 2009 and March 2011 and who met the following inclusion and exclusion criteria ( Table 1) .
The inclusion criteria were as follows:
1. Patients who were 15 years or older 2. Patients who had infiltrative shadows that thought to have appeared acutely and newly on chest radiographic images and not exceeding 2/3 of one lung 3. Patients who had purulent sputum or in whom a bacterial pathogen was presumed to be present in clinical specimens (e.g., the sputum) or who had a positive result in urinary antigen test 4. Patients who had respiratory symptoms (e.g., cough, chest pain, or dyspnea) 5. Patients who could ingest orally 6. Patients who had no concomitant atypical pneumonia as confirmed by rapid diagnosis (ImmunoCard ® Mycoplasma, Meridian, USA) when GRNX therapy was initiated 7. Patients who did not require a combination of other antibiotics or steroids when GRNX therapy was initiated (however, patients undergoing long-term treatment with a low-dose macrolide antibiotic at a fixed dose or patients receiving a drug with a prednisolone conversion of ≤30 mg/day at a fixed dose continued these regimens) 8 . Patients who took no other antibiotics within 7 days before initiation of GRNX therapy (however, patients in whom other antibiotics were considered to be ineffective and infection was detected were allowed)
The exclusion criteria were as follows:
1. Patients who had a history of hypersensitivity to GRNX or other quinolones 2. Patients who were pregnant or possibly pregnant or were lactating 3. Patients who previously enrolled in the study 4. Patients in whom drug efficacy of GRNX was difficult to assess 5. Patients whom the primary physician determined to be inappropriate for registration
(2)-2 Methods
This study was performed as a prospective study using a central registration system.
The patients were registered on the registration center until the day after the beginning of GRNX. Informed consent and ethics committee approval were obtained as required for postmarketing surveillance. The survey items were as follows: patient characteristics (sex, age, inpatient/outpatient, weight, infectious disease diagnosis, severity of pneumonia [A-DROP scoring system], underlying diseases [diseases related to 4 pneumonia], complications [diseases not related to pneumonia], hepatic function disorder before GRNX therapy, renal impairment before GRNX therapy, and history of adverse drug reactions or allergies); antibiotics taken immediately before (within 1 week) initiation of GRNX therapy; administration status of GRNX (dose, number of doses, and administration period); concomitant drugs; combination therapies; clinical symptoms and signs; laboratory tests; bacteriological examinations; clinical efficacy; and adverse events. Rapid diagnosis and serological tests were performed as required.
GRNX was administered under the approved regimen, and the administration period was not limited. Concomitant drugs and combination therapies were not limited.
The observation period was until the termination of GRNX therapy, and adverse events were monitored until 4 days after GRNX therapy was terminated.
(2)-3 Efficacy evaluation
The clinical efficacy and bacteriological efficacy (prevalence of bacteria) were examined. Clinical efficacy was assessed at the termination of GRNX therapy and was classified as "effective," "ineffective," or "evaluation not possible" according to clinical efficacy criteria [7] (Table 2 ). In patients receiving GRNX for 10 days or more, an additional assessment was made on the 10 th day after initiation of GRNX. Bacteriological efficacy (prevalence of bacteria) was classified as bacterial "eradication" or "persistence" according to bacteriological efficacy criteria [7] on the basis the bacteriological examination results before and after GRNX therapy.
Safety was evaluated on the basis of the occurrence of adverse drug reactions. Adverse drug reactions were any events which a causal relationship with GRNX could not be denied during the observation period, such as medically unfavourable and unintended signs and symptoms (e.g., abnormal changes in laboratory tests and clinical symptoms and signs). Exacerbation of the pneumonia because of insufficient response to GRNX was not included.
(2)-4 Assessment of judgment/totalization results
An evaluation committee was formed with 5 members (one principal investigator, three coordinating investigators, and a representative physician) to discuss whether to include the problem cases, the handling of data in cases that deviated from the protocol, the handling of bacterial pathogens, and causal relationships between adverse events and GRNX therapy.
The term "bacterial pathogens" referred to bacteria that were detected at a score of ≥3+ (the level of ≥10 5 colony-forming units/ml) derived from sputum. S. pneumoniae and Haemophilus influenzae detected at a clear level were classified as bacterial 5 pathogens. In addition, positive S. pneumoniae urinary antigen test results and positive Chlamydophila pneumoniae and Mycoplasma pneumoniae serological test results were also obtained to detect bacterial pathogens.
Adverse drug reactions were analyzed using the Medical Dictionary for Regulatory Activities, Japanese version (MedDRA/J, ver. 15.0).
(2)-5 Analysis sets
Efficacy was evaluated in the patients in the efficacy analysis set, which included patients from whom survey forms were collected and who met the inclusion and exclusion criteria and who received GRNX under the approved regimen. The safety was evaluated in the patients in the safety analysis set from whom survey forms were collected and who received GRNX at least one time.
(2)-6 Statistical analysis
Statistical analysis was performed using χ 2 test for comparison, and when the expected values were 5 or less, Fisher's exact probability test was employed.
(3) Results
(3)-1 Analysis sets and patient characteristics
The analysis sets are shown in Figure 1 .
Patient characteristics of efficacy and safety analysis sets are shown in Table 3 .
Among the safety analysis set, 59.0% of patients were male with an average age of 61.6 years and 51.8% (of the total set) were elderly (≥65 years). Moreover, 90.5% were outpatients, 62.2% experienced mild pneumonia according to the A-DROP scoring system, and 36.7% experienced moderate pneumonia. Underlying diseases (diseases related to pneumonia) and complications (diseases not related to pneumonia) were observed in 47.1% and 51.2% of the patients, respectively, both accounting for approximately half of the patients. The maximum daily dose of GRNX was 400 mg, which was administered to a majority of the patients (98.2%). In 13 patients, the dose was adjusted to 200 mg per day by attending physicians because of low weight (<40 kg), advanced renal impairment, advanced age (≥75 years), or the presence of adverse events.
The average administration period was 8.7 ± 3.6 days, with the greatest number of patients at 3 to 7 days (48.6%), followed by 8 to 14 days (44.2%). Patient characteristics in the efficacy analysis set were almost same as those in the safety analysis set.
In patients from whom survey forms were collected, bacterial culture before GRNX 6 therapy was performed in the specimens collected from 635 patients. Rapid diagnosis and serological test of bacterial pathogens were performed in 434 patients; S. pneumoniae urinary antigen test was performed in 399 patients, C. pneumoniae serological test in 88 patients, and M. pneumoniae serological test in 191 patients, respectively. We detected 289 strains of bacterial pathogens from 271 patients. The main bacterial pathogens detected were S. pneumoniae at 45.3% (131/289 strains), followed by H. influenzae at 35.6% (103/289 strains), Moraxella (Branhamella) catarrhalis at 5.9% (17/289 strains), M. pneumoniae at 4.2% (12/289 strains), and C. pneumoniae at 3.1% (9/289 strains) (data not shown).
(3)-2 Clinical efficacy
The clinical efficacy findings are shown in Table 4 . The clinical efficacy for elderly and non-elderly patients is shown in Table 5 .
The efficacy rate was slightly lower in elderly patients with moderate pneumonia. The efficacy rate in the elderly with underlying diseases was lower by approximately 6-10% The efficacy rate in patients receiving antibiotic treatment prior to GRNX therapy (within 7 days before beginning administration) was lower by approximately 3% (89.8%, 53/59 patients) than that in patients not without antibiotic treatment (93.1%, 418/449 patients) ( Table 4 ). The antibiotic treatment before GRNX therapy primarily consisted of oral medications, e.g., clarithromycin (CAM), cefcapene pivoxil (CFPN-PI), and azithromycin (AZM).
The breakdown of 37 patients for whom treatment was determined to be ineffective at 7 the time of the termination of GRNX therapy according to age and underlying diseases is shown in Table 6 .
Efficacy was evaluated in 252 non-elderly patients and 283 elderly patients after the termination of GRNX therapy. The treatment was found to be ineffective in 4.4% (11/252 patients) of the non-elderly and 9.2% (26/283 patients) of the elderly patients. Among the elderly patients with underlying diseases, many had chronic respiratory diseases, and this differed from the underlying diseases of the non-elderly. The elderly and the non-elderly patients had diabetes mellitus, hypertension, rheumatoid arthritis, and other complications, but no differences were observed according to age.
In the efficacy analysis set, 7 patients received concomitant administration of other antibiotics after the initiation of GRNX therapy, and the treatment was effective in 2 out of 6 patients (Table 4 ). GRNX was determined as ineffective in 4 patients for the following reasons; pyrexia at the termination of GRNX administration, insufficient efficacy at the time of admission for atrial fibrillation, progression to pyothorax, diagnosed with mycobacteriosis after initiation of GRNX administration. In addition, 9
patients were suspected with bacterial pneumonia before GRNX therapy, and the bacterial pathogens in these patients were identified as the atypical pathogens C. pneumoniae and M. pneumoniae after the initiation of GRNX therapy; the efficacy rate in these patients for infection of only atypical pathogens was 4/6 patients, and for mixed infection of bacterial and atypical pathogens was 3/3 patients (Table 7) . GRNX was determined as ineffective in 2 patients for the following reasons; insufficient efficacy and cryptogenic organizing pneumonia.
The overall rate of eradication of bacteria was 98.6% (143/145 strains); that of S. pneumoniae was 98.5% (65/66 strains) and H. influenzae was 100% (65/65 strains).
Species that could not be collected in sufficient quantities at the time of GRNX development were Streptococcus species and Enterobacter cloacae, the rates of eradication were 2/2 strains and 1/1 strains (data not shown).
(3)-3 Adverse drug reactions
Overall, 71 adverse drug reactions related with GRNX were observed in 58 patients, and the incidence of adverse drug reaction was 7.9% (58/730 patients) ( Table 8) .
Hepatobiliary disorders and skin and subcutaneous tissue disorders were more frequently reported in non-elderly than in elderly patients. However, no remarkable difference in the incidence of adverse drug reactions overall was noted between non-elderly and elderly patients. Four severe adverse drug reactions were reported in 3 patients; one patient had eosinophilic pneumonia, one patient had atrial fibrillation, and one patient had decreased blood pressure and dyspnea. No patients died of these severe adverse drug reactions. 8 continued in the patient with atrial fibrillation. All the 3 patients recovered after treatment.
(4) Discussion
The clinical efficacy (efficacy rate) of GRNX in patients with suspected bacterial pneumonia, not including hospital-acquired pneumonia, was 92.8% (479/516 patients).
The efficacy of GRNX was good (89.8% [53/59 patients]) even in patients who had received antimicrobial therapies, e.g., CAM, CFPN-PI, and AZM within 1 week before the initiation of GRNX administration and were considered clinical failures. GRNX showed high efficacy (>90%) in non-elderly and elderly patients, but the efficacy rate was significantly lower in the elderly patients (p = 0.0264). Of the elderly patients, only 30% had mild pneumonia and >60% had moderate pneumonia, based on the severity scoring system A-DROP, while among the non-elderly patients, 90% had mild pneumonia. Patients with underlying diseases accounted for approximately 60% of elderly patients; in contrast, only 30% of non-elderly patients had underlying diseases.
We hypothesize that the difference in the efficacy rate between elderly and non-elderly patients was because of differences in the severity of pneumonia and in the prevalence of underlying diseases. The elderly patients in whom GRNX therapy failed often had chronic respiratory diseases (Table 6) , and these patients might have developed pneumonia due to acute exacerbation of chronic respiratory diseases. Bacterial pathogens were not detected in most of these patients, and opportunistic pathogens (e.g., Pseudomonas aeruginosa, Escherichia coli, and Nocardia species) were detected in the amount of + or 2+ score. Furthermore, the efficacy rate of GRNX in the elderly patients might have been lower than that in the non-elderly patients because the elderly patient group included patients with intractable conditions (e.g., aspiration pneumonia). In Japan, the clinical practice guidelines for NHCAP published in 2011 indicate that NHCAP develops frequently in elderly patients with aspiration pneumonia [8] ; however, we were unable to consider this point since this study was conducted before the announcement of the guidelines. In the clinical practice guidelines for NHCAP, GRNX is recommended as one of the empirical treatment drugs for patients who do not require hospitalization [8] ; in this study, the efficacy rate of GRNX was high (>85%) in the populations which could include patients with intractable NHCAP, i.e., elderly patients with moderate pneumonia or with underlying diseases related to pneumonia.
Our results were consistent with those of a GRNX efficacy analysis in >6,000 patients 9 reported by Hori et al. [9] ; they reported that the efficacy rate was >90% and that age, underlying diseases, and complications reduced the effectiveness of GRNX therapy.
In this study, we confirmed the efficacy of GRNX for the administration period in clinical practice, and there was no statistical difference in the efficacy rates between the administration periods of 6-7 days, 8-10 days, and 11-14 days. In patients with mild and moderate pneumonia, the efficacy rates by the administration period of 6-7 days, 8-10 days, and 11-14 days was approximately 90%. As shown in Table 5 , >90% of the patients with moderate pneumonia were elderly. Considering the fact that the efficacy rate in these patients was equivalent to that in the non-elderly patients with pneumonia of the same severity, GRNX is expected to have a therapeutic effect for an administration period of 6-7 days, regardless of whether the patient is elderly or non-elderly. An overseas postmarketing surveillance study of moxifloxacin (MFLX) showed that the clinical efficacy of MFLX was 96.6% for an administration period of 5-10 days in patients with bacterial pneumonia [10] , and we consider that we obtained similar results in our study. Furthermore, 36 patients received long-term GRNX therapy (≥15 days) in the efficacy analysis set. Of these patients, 19 exhibited an improved outcome on the 10 th day after the initiation of GRNX therapy, but the therapy was continued in these patients.
In future studies, it is important to clarify the duration of GRNX outpatient treatment.
The major bacterial pathogens were S. pneumoniae at 45.3% (including 10.7% with positive results only in the urinary antigen test) and H. influenzae at 35.6%. These findings were similar to those reported by Saito et al. [11] and Miyashita et al. [12] . The eradication rates of S. pneumoniae and H. influenzae were >95%, and the overall eradication rate was 98.6%. In the efficacy analysis set, the indicated bacteria were not detected as bacterial pathogens in 345 patients, but GRNX showed high efficacy in these patients at the time of GRNX therapy termination (90.6% [288/318 patients]).
The incidence of adverse drug reactions was 7.9% (58/730 patients). There were no serious issues regarding safety, because no adverse drug reaction specific to GRNX was observed.
In conclusion, we confirmed the usefulness of GRNX for mild to moderate bacterial pneumonia in daily clinical practice. Further studies would be required to clarify the appropriate timing of GRNX termination.
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All other authors report no conflicts of interest. (3) below, if the following items are met; condition (1) fulfills its condition; either condition (2) or (3) satisfies these conditions; and remaining condition does not lead to exacerbation, it is classified as "effective."
(1) Improvement or disappearance of the symptoms and signs of pneumonia A determination of maximum body temperature, cough, sputum (amount, properties), dyspnea, chest pain, or chest rales. (a) Improvement in the symptoms and signs of 1 item or more.
(b) In cases of fever at the initiation of administration (or registered), the fever must improve. If the fever declines after the initiation of administration (or registered), even if body temperature is 37.0°C or more, it will be treated as an improvement. (2) If all abnormalities in chest X-ray shadows improve or disappear Determined on the basis of the density and spread of the chest X-ray shadow.
(3) Improvement or disappearance of inflammation
No exacerbated items and if the following 2 items are met, "Improvements to 9000/μl or less of the peripheral blood white blood cell count" or "Decline from the highest value of CRP." The change within the range of normal level is not considered.
Ineffective
If the above criteria are not "effective," the case is determined to be "ineffective."
Evaluation not possible If it is not possible to determine either "effective" or "ineffective," it is classified as "evaluation not possible." Patients excluded from the safety analysis set a 9
Figure legends
Failure to follow-up 6
Not evaluated for safety 6
Violation of registration 3
Safety analysis set 730
Patients excluded from the efficacy analysis set a 195
Off-label use of GRNX (disease not indicated) 8
Contraindication 3
Did not meet the inclusion criteria 94
Only 1 day of GRNX therapy 3
Off-label use of GRNX (dosage not approved) 6
Not evaluated for efficacy 103
Efficacy analysis set 535
Patients not detected bacterial pathogens a 333
No bacteriological examination/rapid diagnosis/serological test before the initiation of GRNX therapy 29
Inadequate clinical specimens b 4
Off-label use of GRNX (bacteria not indicated) b 303
Bacterial pathogens detection set 202
Patients excluded from the bacteriological efficacy analysis set a 62
Identified bacterial pathogens by rapid diagnosis/serological test only 30
No bacteriological examination on the specified day after the initiation of GRNX therapy 45
Bacteriological efficacy analysis set 140 a Including patients with duplicated reasons for exclusion b Excluding patients who tested positive for S. pneumoniae in the urinary antigen test
